Economic evaluation of the home blood pressure telemonitoring and pharmacist case management to control hypertension (Hyperlink) trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Pharmacist‐managed (team‐based) care for hypertension with home blood pressure monitoring support interventions has been widely studied and shown to be effective in improving rates of hypertension control and lowering blood pressure; however, few studies have evaluated the economic considerations related to bringing these programs into usual practice. Objective: To analyze the economic outcomes of the Home Blood Pressure Telemonitoring and Case Management to Control Hypertension (Hyperlink) study, a cluster randomized controlled trial which used home blood pressure telemonitoring and pharmacist case management to achieve better blood pressure control in patients with uncontrolled hypertension was conducted. Methods: A prospective analysis compared differences in medical costs and encounters in the Hyperlink telemonitoring intervention and usual care groups in the 12 months pre‐ and postenrollment using medical and pharmacy insurance claims from a health care sector perspective. Generalized estimating equation models were used to estimate differences between the groups over time. These results, combined with previously published prospective study results on intervention costs and blood pressure outcomes, were used to estimate cost‐effectiveness measures for blood pressure control and reduction. Findings: Total medical costs in the intervention group were lower compared with the usual care group by an average of $281 per person, but this difference was not statistically significant. Clinic‐based office visit, radiology, pharmacy and hospital costs were also nonsignificantly lower in the intervention group. Statistically significant differences were found in lipid‐related laboratory costs (higher) and in hypertension‐related (higher) and lipid‐related (lower) pharmacy costs. Patterns in medical costs were similar for medical encounters. On average, the intervention cost $7337 per person achieving hypertension control and $139 or $265 per mm Hg reduction in systolic or diastolic blood pressure, respectively. Conclusions: Home blood pressure monitoring and pharmacist case management to improve hypertension care can be implemented without increasing, and potentially reducing, overall medical care costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
A Suggestion for Using Powerful and Informative Tests of Normality
D'agostino, R. B., Belanger, A., & D'agostino, R. B. (1990) · The American Statistician · doi:10.2307/2684359 · Cited by 1,809
Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., & Sullivan, S. D. (2015) · Value in Health · doi:10.1016/j.jval.2015.02.001 · Cited by 811
Margolis, K. L., Asche, S. E., Bergdall, A. R., Dehmer, S. P., Groen, S. E., Kadrmas, H. M., Kerby, T. J., Klotzle, K. J., Maciosek, M. V., Michels, R. D., et al. (2013) · JAMA · doi:10.1001/jama.2013.6549 · Cited by 591
Self-citationThe “Million Hearts” Initiative — Preventing Heart Attacks and Strokes
Frieden, T. R., & Berwick, D. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1110421 · Cited by 310 · cited 2×
“In a model-based analysis of the nationwide US adoption of a slightly less effective team-based intervention program at about 40% of the cost, we found that over 600 000 CVD events could be prevented and net social cost savings could be achieved over 10 years.27 Even with moderately higher costs, a program with the po…”
BackgroundEconomic evaluation of pharmacist involvement in disease management in a community pharmacy setting
Munroe, W. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80078-1 · Cited by 122
Economic evaluation of telephone self-management interventions for blood pressure control
Wang, V., Smith, V. A., Bosworth, H. B., Oddone, E. Z., Olsen, M. K., McCant, F., Powers, B. J., & Van Houtven, C. H. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.03.016 · Cited by 49
Datta, S. K., Oddone, E. Z., Olsen, M. K., Orr, M., McCant, F., Gentry, P., & Bosworth, H. B. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.05.024 · Cited by 42
Cited by
Shimbo, D., Artinian, N. T., Basile, J. N., Krakoff, L. R., Margolis, K. L., Rakotz, M. K., Wozniak, G., & On behalf of the American Heart Association and the American Medical Association (2020) · Circulation · doi:10.1161/cir.0000000000000803 · Cited by 389
Self-citationOmboni, S., McManus, R. J., Bosworth, H. B., Chappell, L. C., Green, B. B., Kario, K., Logan, A. G., Magid, D. J., Mckinstry, B., Margolis, K. L., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15873 · Cited by 307
Self-citationEconomic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review
De Guzman, K. R., Snoswell, C. L., Taylor, M. L., Gray, L. C., & Caffery, L. J. (2022) · Value in Health · doi:10.1016/j.jval.2021.12.001 · Cited by 83
Margolis, K. L., Dehmer, S. P., Sperl-Hillen, J., O’Connor, P. J., Asche, S. E., Bergdall, A. R., Green, B. B., Nyboer, R. A., Pawloski, P. A., Trower, N. K., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15492 · Cited by 48
“Prior analysis revealed that the change in costs from the 12 month intervention period compared with previous 12 months for clinic visits, total pharmacy, laboratory, and radiology did not differ significantly between TI and UC patients.(15) Therefore, these costs are not included in intervention costs.”
ResultSelf-citationHayek, M. A., Giannouchos, T., Lawley, M., & Kum, H.-C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.44372 · Cited by 32
Metadata
- Authors
- Dehmer, S. P., Maciosek, M. V., Trower, N. K., Asche, S. E., Bergdall, A. R., Nyboer, R. A., O'Connor, P. J., Pawloski, P. A., Sperl‐Hillen, J. M., Green, B. B., & Margolis, K. L.
- Venue
- JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
- Publisher
- Wiley
- Published
- 2018-06-25
- Volume
- 1
- Issue
- 1
- Pages
- 21-30
- ISSN
- 2574-9870 (ISSN-L)
- OpenAlex
- W2897832367
- Cited by
- 46
- References
- 10
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.